Trial ID or NCT#

NCT01926197

Status

RECRUITING

Purpose

The goal of this study is to determine the safety and efficacy of a chemotherapy regimen known as Modified FOLFIRINOX (mFFX) alone or with the addition of Stereotactic Body Radiotherapy (SBRT). We hope to learn if this new treatment combination helps to control the disease and improve survival for patients with locally advanced pancreatic cancer.

Official Title

A Randomized Phase III Study Evaluating Modified FOLFIRINOX (mFFX) With or Without Stereotactic Body Radiotherapy (SBRT) in the Treatment of Locally Advanced Pancreatic Cancer

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Daniel Chang
Radiation oncologist
Sue and Bob McCollum Professor
Albert Koong, MD, PhD

Contact us to find out if this trial is right for you.

CONTACT

Rachel Freiberg
(650) 725-0438